



(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete If Known

Application Number	10/500,964
Filing Date	July 8, 2004
First Named Inventor	Keizo SUGASAWA
Art Unit	1625
Examiner Name	C. C. Chang
Attorney Docket Number	401.1013US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code* -Number* -Kind Code* (if known)				
	B1	EP-0518731-B1	08-26-1998	Sanofi SA		Abstr. (See also US 5,314,889)
TC	B2	WO-02/053160-A1	07-11-2002	Alteon, Inc.		
	B3	WO-03/075921-A2	09-18-2003	Transtech Pharma, Inc.		
	B4	WO-03/084544-A2	10-16-2003	CV Therapeutics, Inc.		
TC	B5	WO-04/002481-A1	01-08-2004	Novo Nordisk A/S		

Examiner Signature	/Celia Chang/	Date Considered	06/24/2009
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference coincide, whether or not citation is in conformance with MPPE 609. Draw line through citation if not in conformance and not considered. Enclose copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.89b(2)(iii)) because that application was filed after year 2000, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kinds/Codes of USPTO Patent Documents at www.uspto.gov/cfo/MPPE%20609.pdf. Enter office that issued the application by the country name, e.g., Japan, etc., indicating the country of origin of the invention. The country code of the Examiner must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/500,964
Filing Date	July 8, 2004
First Named Inventor	Keizo SUGASAWA
Art Unit	1625
Examiner Name	C. C. Chang
Attorney Docket Number	401.1013US

Sheet	2	of	3
-------	---	----	---

[illegible][illegible]

Examiner Signature	/Celia Chang/	Date Considered	06/24/2009
-----------------------	---------------	--------------------	------------

***EXAMINER:** Initial if reference concides, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and note discrepancy. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (option). See US Kinds Codes of USPTO Patent Documents at www.uspto.gov/ip/mpep/101.4. * Enter Office that issued the cited patent or publication. * Indicate the year of the cited document, the indication of the year of the origin of the Employer must precede the serial number of the patent document. * English document by the appropriate symbols as indicated in the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/500,964	
			Filing Date	July 8, 2004	
			First Named Inventor	Keizo SUGASAWA	
			Art Unit	1625	
			Examiner Name	C. C. Chang	
Sheet	3	of	3	Attorney Docket Number	401.1013US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/CC/	C1	Braga, Dario et al., "Making crystals from crystals: a green route to crystal engineering and polymorphism," <i>Chem. Commun.</i> , Vol. 29:3635-3645 (2005)		
	C2	Morissette, Sherry et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids," <i>Advanced Drug Delivery Reviews</i> , Vol. 58:275-300 (2004)		
/CC/	C3	Vippagunta, Sudha et al., "Crystalline solids," <i>Advanced Drug Delivery Reviews</i> , Vol. 48:3-26 (2001) (Abstract)		
Examiner Signature		/Celia Chang/	Date Considered	06/24/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.